Compare Danaher Corporation (DHR) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Schlumberger NV — how do they compare? Danaher Corporation trades at $217.88 (market cap $152.87B), while Schlumberger NV trades at $48.97 (market cap $72.69B). The key difference: Danaher Corporation is far larger — about 2.1× Schlumberger NV's market cap, and Schlumberger NV pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Schlumberger NV for 99 Days on average.
| DHR | SLB | |
|---|---|---|
Market Cap | $152.87B | $72.69B |
Volume | 5,228,698 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $242.05 | $60.10 |
52-Week Low | $161.91 | $31.72 |
Typical Hold Time | 69 Days | 99 Days |
Enterprise Value | $175.08B | $81.42B |
Dividend Yield | 0.74% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
SLB trades at $47.96, down 4.08% in the last session, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats and a robust $35.71B revenue base, though 2025 net income declined to $3.37B. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility, supporting analyst optimism with an 84.85% buy rating and $64.58 consensus price target.
SLB presents a compelling value opportunity with significant upside to analyst targets, driven by expanding international contracts and solid cash flow generation. Key risks include oil price volatility and execution challenges in new projects. The stock's current technical weakness may offer an attractive entry point for long-term investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
